[CLSTR]
< Back to situation

[REVISION HISTORY]

Corporate GLP-1 medication coverage trends

Updated 2 times since CLSTR started tracking revisions of this situation.

What changed

2026-08-09 23:45 UTC → 2026-09-01 19:24 UTC · added removed

Major U.S. employers are adopting diverging strategies regarding the coverage of GLP-1 weight-loss medications, such as Ozempic and Ozempic, Wegovy, and Zepbound, due to rising costs. Bank of America has committed over $250 million annually from its roughly $2 billion healthcare budget to provide these drugs and associated health coaching to its 210,000 210,000-plus employees. The bank views this as a CEO Brian Moynihan stated the program aims to improve short- and long-term investment in employee health health, citing reduced heart-disease risk and productivity. productivity gains, noting the investment remains worthwhile even if employees leave before benefiting. This expenditure represents more than 12% of the bank’s total healthcare budget. In contrast, other many large corporations are scaling back. Starbucks announced it will stop covering GLP-1 medications prescribed specifically for weight loss starting in October, though it may still cover them will continue coverage for other medical conditions. This follows similar cost-cutting measures by companies such as conditions like diabetes. Other companies, including PwC, Cigna, and Allina Health. Recent HCA Healthcare, have also reduced or eliminated support for weight-loss purposes. Industry data reflects this tightening of benefits. The percentage of large employers offering these medications for obesity dropped from 72% in 2025 to 60% in 2026. A survey by the International Foundation of Employee Benefit Plans highlights the increasing financial impact found that only 36% of these medications: U.S. businesses currently cover GLP-1s for weight loss, with 14% of employers planning to reduce or eliminate such coverage by 2027 to maintain financial viability. Previously, GLP-1 drugs accounted for 11.4% of total annual corporate claims last year, rising claims, up from 6.9% in 2023.

Versions

  1. 2026-09-01 19:24 UTC Corporate GLP-1 medication coverage trends
  2. 2026-08-09 23:45 UTC Corporate GLP-1 medication coverage trends
  3. 2026-08-09 12:34 UTC Corporate GLP-1 medication coverage trends

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.